Orientbio

At a glance

Orientbio filed 43 disclosures in the last 12 months, including 8 insider, 5 5% holder, 1 buyback and 1 issuance. The most recent key filing was on Sep 17.

Revenue for 2025 was ₩29.4B, up 5% on 2024. It made an operating loss of ₩3.1B. Debt was 18% of equity at year end.

The 2025 annual report lists 123 employees with an average tenure of 4.4 years and average pay of ₩32.9M, #1815 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩145M each on average. It paid no cash dividend for 2025. ㈜오리엔트 and related parties held 35.60% at year end.

From the 2025 annual report

Staff: 123 (61 men, 62 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩4.1B. Directors and auditors: 5, paid ₩723M in total.

No cash dividend was paid for 2025.

Largest shareholder

㈜오리엔트 holds 23.99%; with 3 related parties the group holds 35.60% of common shares at year end.

Auditor: 성현회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary